• Targets the TLR4 pathway’s inflammatory cascades and immune responses that drive cell death
• In development for prevention and treatment of ACLF grades 1 and 2
• Plans to develop for the treatment of hyperammonemia and hepatic encephalopathy

Direct investment via Hepyx